Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
Stopped early · Phase 2
Conditions studied: Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
In brief
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle. Poly-ICLC is a compound that has been used to help the body in its fight against cancer.
Key facts
- Study ID
- NCT01984892
- Run by
- Nina Bhardwaj
- People needed
- 8
- Starts
- 2013-11-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2018-01-23
Who can join
Age: 14 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed diagnosis of melanoma, squamous head and neck cancer, sarcoma, squamous cell carcinoma of the skin, basal cell skin cancer, or breast cancer
- Sarcoma Patients must be @ least14 yrs of age; all others 18 yrs of age or older.
- Un-resectable disease. Patients with resectable disease may be enrolled after having refused surgery and documented consultation with a surgeon.
- Disease progressed through @ least 1 systemic therapy or through local irradiation within the preceding 6 mos.
- Radiologically or visually measurable recurrent or metastatic disease and @ least 10mm in longest dimension.
- At least 1 accessible primary or metastatic tumor site that can be readily injected IT with poly-ICLC with or without ultrasound guidance. Lesion can be superficial cutaneous, subcutaneous or within a readily accessible lymph node \& must measure @ least 10mm in longest dimension.
- Tumor site injection cannot have been irradiated within 8 wks of C1D1
- ECOG performance status ≤ 2.
- Normal hematologic, renal \& liver function. INR<2 if off of anticoagulation. Patients on anticoagulation therapy with an INR>2 may be enrolled at the discretion of the investigator.
- Patients able to provide informed consent.
- Must agree to follow acceptable birth control methods and continue for @ least 2 mos. after last poly-ICLC dose. Women of childbearing potential must have a (-) pregnancy test.
You may not qualify if…
- Serious concurrent infection or medical illness.
- Bulky intracranial metastatic disease with shift of midline structures or progressive brain metastasis. Administration of immunotherapy or conventional chemotherapy treatments for metastatic cancer within 4 wks of C1D1
- Radiation treatments within 4 wks of C1D1
- AIDS defined as a CD4 count < then 200 in the context of HIV sero-positivity or chronically is taking immunosuppressive medication such as steroids or transplant related medications.
- Life expectancy of < than 6 mos.
Where it is running
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.